PCA: A TFNA-Based Targeted Nucleic Acid Nanocomposite Hydrogel for the Treatment of Androgenetic Alopecia Through the Promotion of Angiogenesis and Hair Follicle Stem Cell Proliferation

The study introduces PCA, a novel tFNA-based targeted nanocomposite hydrogel, for treating androgenetic alopecia (AGA) by enhancing angiogenesis and hair follicle stem cell proliferation. PCA facilitates sustained delivery of the therapeutic complex Apt02-tFNA-miR210 (ATM). In an AGA mouse model, PCA significantly promoted hair regeneration by activating VEGF and Wnt/β-catenin signaling pathways, increasing blood vessel formation, and stimulating hair follicle stem cells. This approach overcomes current AGA treatment limitations, showing promise as a safe and effective nanotherapeutic strategy for hair loss.